Millipore Sigma aims to create a platform capable of expressing viral antigen proteins for vaccine production in CHO cells at small scale in 14–16 weeks. This will be achieved by developing versatile workflows, gene expression vectors that can be adapted for novel antigen proteins, and templated small scale bioreactor processes to improve viral antigen product yields.
The goals of this project are to:
The project's successful completion will enable faster delivery of valuable reagents to scientists and, specifically, vaccines (e.g., coronavirus) and biologic medicines to patients by reducing the overall timeline for protein production by more than 50%.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.